Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin- cyclophosphamide;Tratamiento neoadyuvante del cáncer de mama localmente avanzado. Comparación de dos esquemas a base de docetaxel-epirrubicina versus 5-fluoraciloepirrubicina-ciclofosfamida

Cirugia y Cirujanos

Volumn 76, Issue 1, 2008, Pages 23-28

  Cortés Flores, Ana Olivia ^a   Morgan Villela, Gilberto ^a   Castro Cervantes, Juan Manuel ^a   Vázquez Camacho, Gonzalo ^a   Fuentes Orozco, Clotilde ^a   González Ojeda, Alejandro ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Breast cancer; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TAXOID;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EPIRUBICIN; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 70450105787     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Neal AJ, Hoskin PJ. Clinical Oncology. Basic Principles and Practice. 3rd ed. London: Arnold;2003. pp. 68-85.
2. Dirección General de Epidemiología. Registro Nacional de Cáncer. México: Secretaría de Salud; 1996.
3. Valero V, Buzdar A, Hortobagyi G. Locally advanced breast cancer. Oncologist 1996;1:8-17.
4. Harris JR, Lippman ME, Veronesi U. Breast cancer. N Engl J Med 1992;327:319-328.
5. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist 2002;7:239-245.
6. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
7. Charfare H, Limongelli S, Puruschotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005;92:14-23.
8. Insa A, Chirivella I, Lluch A. Tratamiento neoadyuvante del cáncer de mama operable. Med Clin (Barc) 2006;126:295-303.
9. Sachelarie I, Groosbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006;11:574-589.
10. Guarneri V, Frassoldati A, Giovannelli S, Borghi F, Conte P. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. Cancer Lett 2007;248:175-185.
11. von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother 2007;8:485-495.
12. Mieog JSD, van der Hage JA, van de Velde CJH. Preoperative chemotherapy for women with operable breast cancer (review). Cochcrane database of Systematic Reviews 2007; 2. Art. No:10.1002/14651858.CD005002.pub.2
13. National Cancer Institute. www.cancer.gov
14. Nabholtz JM, Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 2001;6(suppl):5-12.
15. de Matteis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002;94:895-901.
16. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
17. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
18. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999;17:2341-2354.
19. Gradishar WJ. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer. Clin Breast Cancer 2001;2:S31-35.
20. Sessa C, Pagani O. Docetaxel and epirubicin in advanced breast cancer. Oncologist 2001;6(suppl):13-16.
21. Gradishar WJ, Wedam SB, Jahanzeb M, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005;16:1297-1304.
22. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.
23. Reitsamer R, Peintinger F, Prokop E, Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005;16:867-870.
24. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotheraphy for breast cancer. J Clin Oncol 2000;18:3480-3486.
25. Tfayli A, Holter J, Brova A, et al. Activity of combination chemotherapy docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer. Anticancer Res 2006;26:4911-4916.